KR20210040180A - 프로스타글란딘을 피하 지방으로 국소 전달하기 위한 조성물 및 방법 - Google Patents

프로스타글란딘을 피하 지방으로 국소 전달하기 위한 조성물 및 방법 Download PDF

Info

Publication number
KR20210040180A
KR20210040180A KR1020217009848A KR20217009848A KR20210040180A KR 20210040180 A KR20210040180 A KR 20210040180A KR 1020217009848 A KR1020217009848 A KR 1020217009848A KR 20217009848 A KR20217009848 A KR 20217009848A KR 20210040180 A KR20210040180 A KR 20210040180A
Authority
KR
South Korea
Prior art keywords
certain embodiments
alkyl
optionally substituted
composition
alkenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020217009848A
Other languages
English (en)
Korean (ko)
Inventor
마이클 에스. 싱어
무라트 브이. 칼라요굴루
Original Assignee
토포카인 쎄라퓨틱스, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50933526&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR20210040180(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 토포카인 쎄라퓨틱스, 인코포레이티드 filed Critical 토포카인 쎄라퓨틱스, 인코포레이티드
Publication of KR20210040180A publication Critical patent/KR20210040180A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
KR1020217009848A 2013-05-10 2014-05-09 프로스타글란딘을 피하 지방으로 국소 전달하기 위한 조성물 및 방법 Ceased KR20210040180A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361822139P 2013-05-10 2013-05-10
US61/822,139 2013-05-10
PCT/US2014/037512 WO2014183045A2 (en) 2013-05-10 2014-05-09 Compositions and methods for topical delivery of prostaglandins to subcutaneous fat

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020207009488A Division KR20200037458A (ko) 2013-05-10 2014-05-09 프로스타글란딘을 피하 지방으로 국소 전달하기 위한 조성물 및 방법

Publications (1)

Publication Number Publication Date
KR20210040180A true KR20210040180A (ko) 2021-04-12

Family

ID=50933526

Family Applications (4)

Application Number Title Priority Date Filing Date
KR1020157032864A Expired - Fee Related KR101651450B1 (ko) 2013-05-10 2014-05-09 프로스타글란딘을 피하 지방으로 국소 전달하기 위한 조성물 및 방법
KR1020207009488A Ceased KR20200037458A (ko) 2013-05-10 2014-05-09 프로스타글란딘을 피하 지방으로 국소 전달하기 위한 조성물 및 방법
KR1020217009848A Ceased KR20210040180A (ko) 2013-05-10 2014-05-09 프로스타글란딘을 피하 지방으로 국소 전달하기 위한 조성물 및 방법
KR1020167022712A Expired - Fee Related KR102098987B1 (ko) 2013-05-10 2014-05-09 프로스타글란딘을 피하 지방으로 국소 전달하기 위한 조성물 및 방법

Family Applications Before (2)

Application Number Title Priority Date Filing Date
KR1020157032864A Expired - Fee Related KR101651450B1 (ko) 2013-05-10 2014-05-09 프로스타글란딘을 피하 지방으로 국소 전달하기 위한 조성물 및 방법
KR1020207009488A Ceased KR20200037458A (ko) 2013-05-10 2014-05-09 프로스타글란딘을 피하 지방으로 국소 전달하기 위한 조성물 및 방법

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020167022712A Expired - Fee Related KR102098987B1 (ko) 2013-05-10 2014-05-09 프로스타글란딘을 피하 지방으로 국소 전달하기 위한 조성물 및 방법

Country Status (27)

Country Link
US (5) US9040584B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (3) EP3124015B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (2) JP5930568B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
KR (4) KR101651450B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CN (2) CN109966240A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (3) AU2014262495B9 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR (1) BR112015028290A2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA2907721C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CL (1) CL2015003270A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CR (1) CR20150652A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CY (1) CY1118654T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DK (2) DK3124015T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES (2) ES2604160T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HU (2) HUE030977T2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IL (2) IL240807A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MX (2) MX347969B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MY (1) MY183193A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NO (1) NO2753788T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NZ (1) NZ712784A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PH (1) PH12015502503A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PL (2) PL2863886T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PT (2) PT2863886T (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
RU (1) RU2635864C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SG (2) SG10201604659QA (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SI (1) SI2863886T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
WO (1) WO2014183045A2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ZA (1) ZA201507702B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007111806A2 (en) 2006-03-23 2007-10-04 Massachusetts Eye And Ear Infirmary Cyclopentane heptanoic acid compounds for reducing body fat
US20110124736A1 (en) 2009-11-09 2011-05-26 Allergan, Inc. Compositions and methods for stimulating hair growth
JP5778781B2 (ja) 2011-01-19 2015-09-16 トポカイン セラピューティックス， インコーポレイテッド 代謝症候群を治療する方法および組成物
US8426471B1 (en) 2011-12-19 2013-04-23 Topokine Therapeutics, Inc. Methods and compositions for reducing body fat and adipocytes
NO2753788T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) * 2013-05-10 2018-06-16
US9820993B2 (en) 2013-05-15 2017-11-21 Topokine Therapeutics, Inc. Methods and compositions for topical delivery of prostaglandins to subcutaneous fat
WO2015200425A1 (en) 2014-06-27 2015-12-30 Topokine Therapeutics, Inc. Topical dosage regimen
MX385254B (es) * 2015-04-30 2025-03-14 Allergan Inc Uso de analogos de bimatoprost para el tratamiento de la reduccion de grasa corporal en un sujeto.
MA45760A (fr) * 2015-06-09 2019-06-05 Thesan Pharmaceuticals Inc Bêta-naphthoisoflavones, compositions contenant celles-ci et leurs utilisations
CA2990856A1 (en) * 2015-06-23 2016-12-29 Thesan Pharmaceuticals, Inc. 12h-benzo[a]xanthen-12-ones, compositions containing, and uses of, same
US20180179174A1 (en) * 2015-06-23 2018-06-28 Thesan Pharmaceuticals, Inc. 12H-BENZO[b]XANTHEN-12-ONES, COMPOSITIONS CONTAINING, AND USES OF, SAME
BR112018007434A2 (pt) 2015-10-27 2018-10-23 Cytozyme Animal Nutrition Inc composições para nutrição animal, usos e métodos relacionados
US10674746B2 (en) 2015-10-27 2020-06-09 Cytozyme Animal Nutrition, Inc. Animal nutrition compositions and related methods
CN107773758B (zh) * 2016-08-31 2021-02-26 程辉 一种用于消除皮下脂肪沉积的组合物及其应用
EP4509118A3 (en) * 2018-09-19 2025-05-14 ModernaTX, Inc. High-purity peg lipids and uses thereof
US10835502B2 (en) 2018-10-16 2020-11-17 Polithera, Inc. Alcohol-based compositions and uses thereof
PL427837A1 (pl) * 2018-11-22 2020-06-01 Gbj Pharma Spółka Z Ograniczoną Odpowiedzialnością Systemy do ciągłego obwodowego podawania latanoprostu dla obniżania ciśnienia śródgałkowego
CA3136843A1 (en) * 2019-04-24 2020-10-29 Follicum Ab Topical formulation
US11452703B2 (en) * 2020-05-21 2022-09-27 Peregrine Ophthalmic PTE LTD. Methods and compositions for reducing adipocyte numbers
JP6855026B1 (ja) * 2020-11-09 2021-04-07 東亜薬品株式会社 タフルプロスト点眼液
CN117651542A (zh) * 2021-07-12 2024-03-05 美国奥科视光有限公司 皮肤保湿组合物

Family Cites Families (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4270537A (en) 1979-11-19 1981-06-02 Romaine Richard A Automatic hypodermic syringe
US4599353A (en) 1982-05-03 1986-07-08 The Trustees Of Columbia University In The City Of New York Use of eicosanoids and their derivatives for treatment of ocular hypertension and glaucoma
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US4886499A (en) 1986-12-18 1989-12-12 Hoffmann-La Roche Inc. Portable injection appliance
GB8704027D0 (en) 1987-02-20 1987-03-25 Owen Mumford Ltd Syringe needle combination
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US4940460A (en) 1987-06-19 1990-07-10 Bioject, Inc. Patient-fillable and non-invasive hypodermic injection device assembly
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
EP0302147A1 (en) 1987-08-03 1989-02-08 The Procter & Gamble Company Topical tanning compositions
US5339163A (en) 1988-03-16 1994-08-16 Canon Kabushiki Kaisha Automatic exposure control device using plural image plane detection areas
DE68929563D1 (de) 1988-09-06 2009-03-05 Pfizer Health Ab Prostaglandin-Derivate zur Behandlung von Glaukom und ocularer Hypertension
US5296504A (en) 1988-09-06 1994-03-22 Kabi Pharmacia Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension
FR2638359A1 (fr) 1988-11-03 1990-05-04 Tino Dalto Guide de seringue avec reglage de la profondeur de penetration de l'aiguille dans la peau
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5011062A (en) 1990-05-09 1991-04-30 Delco Electronics Corporation Ultrasonic welding mask
US5190521A (en) 1990-08-22 1993-03-02 Tecnol Medical Products, Inc. Apparatus and method for raising a skin wheal and anesthetizing skin
US5527288A (en) 1990-12-13 1996-06-18 Elan Medical Technologies Limited Intradermal drug delivery device and method for intradermal delivery of drugs
GB9118204D0 (en) 1991-08-23 1991-10-09 Weston Terence E Needle-less injector
SE9102652D0 (sv) 1991-09-13 1991-09-13 Kabi Pharmacia Ab Injection needle arrangement
US5328483A (en) 1992-02-27 1994-07-12 Jacoby Richard M Intradermal injection device with medication and needle guard
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
US5972991A (en) 1992-09-21 1999-10-26 Allergan Cyclopentane heptan(ene) oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents
US5688819A (en) 1992-09-21 1997-11-18 Allergan Cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents
US5569189A (en) 1992-09-28 1996-10-29 Equidyne Systems, Inc. hypodermic jet injector
US5334144A (en) 1992-10-30 1994-08-02 Becton, Dickinson And Company Single use disposable needleless injector
US5510383A (en) 1993-08-03 1996-04-23 Alcon Laboratories, Inc. Use of cloprostenol, fluprostenol and their salts and esters to treat glaucoma and ocular hypertension
JPH07138258A (ja) 1993-11-16 1995-05-30 Taiho Yakuhin Kogyo Kk チアゾリジンジオン誘導体又はその塩
US5380760A (en) * 1993-11-19 1995-01-10 Minnesota Mining And Manufacturing Company Transdermal prostaglandin composition
WO1995024176A1 (en) 1994-03-07 1995-09-14 Bioject, Inc. Ampule filling device
US5466220A (en) 1994-03-08 1995-11-14 Bioject, Inc. Drug vial mixing and transfer device
US5631287A (en) 1994-12-22 1997-05-20 Alcon Laboratories, Inc. Storage-stable prostaglandin compositions
US5599302A (en) 1995-01-09 1997-02-04 Medi-Ject Corporation Medical injection system and method, gas spring thereof and launching device using gas spring
US5730723A (en) 1995-10-10 1998-03-24 Visionary Medical Products Corporation, Inc. Gas pressured needle-less injection device and method
US5893397A (en) 1996-01-12 1999-04-13 Bioject Inc. Medication vial/syringe liquid-transfer apparatus
GB9607549D0 (en) 1996-04-11 1996-06-12 Weston Medical Ltd Spring-powered dispensing device
RU2157689C2 (ru) 1996-07-24 2000-10-20 Панацея Биотек Лтд. Фармацевтические композиции терапевтического антивоспалительного и болеутоляющего средства для местного нанесения и способ их получения
JP3480549B2 (ja) 1996-12-26 2003-12-22 参天製薬株式会社 ジフルオロプロスタグランジン誘導体およびその用途
WO1998033497A1 (en) 1997-02-04 1998-08-06 Johnstone Murray A Method of enhancing hair growth
US5993412A (en) 1997-05-19 1999-11-30 Bioject, Inc. Injection apparatus
US6646001B2 (en) 1997-12-19 2003-11-11 Alcon Manufacturing, Ltd. Use of non-steroidal anti-inflammatory agents in combination with prostaglandin FP receptor agonists to treat glaucoma and ocular hypertension
AU1709699A (en) 1997-12-22 1999-07-12 Alcon Laboratories, Inc. 13-oxa prostaglandins for the treatment of glaucoma and ocular hypertension
IT1298087B1 (it) 1998-01-08 1999-12-20 Fiderm S R L Dispositivo per il controllo della profondita' di penetrazione di un ago, in particolare applicabile ad una siringa per iniezioni
US6235781B1 (en) 1998-07-14 2001-05-22 Alcon Laboratories, Inc. Prostaglandin product
ES2311507T3 (es) 2000-02-10 2009-02-16 MASSACHUSETTS EYE & EAR INFIRMARY Terapia fotodinamica para tratamiento de afecciones oftalmicas.
US20020172693A1 (en) 2000-03-31 2002-11-21 Delong Michell Anthony Compositions and methods for treating hair loss using non-naturally occurring prostaglandins
ES2172415B2 (es) 2000-07-28 2003-11-16 Univ Madrid Complutense Tratamiento del glaucoma y la hipertension ocular por medio de un analogo de la melatonina.
CA2442683A1 (en) 2001-03-27 2002-10-17 The Regents Of The University Of California Methods, compounds, and compositions for reducing body fat and modulating fatty acid metabolism
GB0202159D0 (en) 2002-01-30 2002-03-20 Sensor Highway Ltd OPtical time domain reflectometry
IL147921A0 (en) 2002-01-31 2002-08-14 Abdulrazik Mohammad A method for treating central nervous system disorders by ocular dosing
US7351404B2 (en) 2002-02-04 2008-04-01 Allergan, Inc. Method of enhancing hair growth
JP4387639B2 (ja) * 2002-07-16 2009-12-16 久光製薬株式会社 経皮吸収製剤
US6864282B2 (en) 2002-08-05 2005-03-08 Allergan, Inc. 9,11-cycloendoperoxide pro-drugs of prostaglandin analogues for treatment of ocular hypertension and glaucoma
US20040115234A1 (en) 2002-09-24 2004-06-17 Gewirtz Joan T. Cosmetic composition
US8114911B2 (en) 2002-10-23 2012-02-14 Sucampo Ag Prostaglandin compounds for the treatment of obesity
US7074827B2 (en) 2002-10-24 2006-07-11 Sucampo Ag (Usa) Inc. Method for treating ocular hypertension and glaucoma
MXPA05009816A (es) 2003-03-21 2005-12-05 Nexmed Holdings Inc Composiciones y metodos para el tratamiento de la eyaculacion precoz.
US6933289B2 (en) 2003-07-01 2005-08-23 Allergan, Inc. Inhibition of irritating side effects associated with use of a topical ophthalmic medication
US20050058614A1 (en) 2003-09-15 2005-03-17 Allergan, Inc. Methods for the treatment of gray hair using cyclopentane(ene) heptan(en)oic acid amides
US7070768B2 (en) 2003-09-25 2006-07-04 Allergan, Inc. Method for imparting artificial tan to human skin
US7993634B2 (en) 2004-04-30 2011-08-09 Allergan, Inc. Oil-in-oil emulsified polymeric implants containing a hypotensive lipid and related methods
US8722097B2 (en) 2004-04-30 2014-05-13 Allergan, Inc. Oil-in-water method for making polymeric implants containing a hypotensive lipid
DK2422789T3 (en) 2004-05-19 2018-02-26 Los Angeles Biomedical Res Inst Harbor Ucla Medical Ct INJECTABLE COMPOSITION CONTAINING SODIUM DEOXYCHOLATE
ES2314354T3 (es) 2004-11-09 2009-03-16 Novagali Pharma S.A. Emulsion de tipo aceite en agua con baja concentracion de agente cationico y potencial zeta positivo.
US20080233053A1 (en) 2005-02-07 2008-09-25 Pharmalight Inc. Method and Device for Ophthalmic Administration of Active Pharmaceutical Ingredients
CN101151034B (zh) 2005-03-31 2012-06-06 旭硝子株式会社 含有前列腺素F2α衍生物作为有效成分的视网膜神经细胞保护剂
BRPI0613034A8 (pt) 2005-07-14 2018-01-02 Lipothera Inc formulação injetável para acúmulo de tecido adiposo, formulação injetável e método para o tratamento de acúmulo de gordura, e, método para reduzir o tecido adiposo.
WO2007011806A2 (en) * 2005-07-18 2007-01-25 Soundquest, Inc. Behind-the-ear auditory device
JP5688496B2 (ja) 2005-08-29 2015-03-25 アラヴァ・バイオ‐テック・リミテッドＡｒａｖａ Ｂｉｏ‐Ｔｅｃｈ Ｌｔｄ． 糖尿病および皮膚の老化を予防および治療するための方法および組成物
US9393218B2 (en) 2005-12-23 2016-07-19 Epinamics Gmbh Use of film-forming hair care polymers from the group of polyurethanes and pharmaceutical preparations and patches that contain these polymers
WO2007111806A2 (en) 2006-03-23 2007-10-04 Massachusetts Eye And Ear Infirmary Cyclopentane heptanoic acid compounds for reducing body fat
RU2325912C1 (ru) * 2006-09-06 2008-06-10 Открытое акционерное общество "Химико-фармацевтический комбинат "АКРИХИН" (ОАО "АКРИХИН") Фармацевтическая композиция противовоспалительного и антимикробного действия в форме мази на гидрофобной основе для лечения кожных заболеваний (варианты)
US8796282B2 (en) 2007-03-28 2014-08-05 Case Western Reserve University Method of treating dermatological disorders
WO2008120249A1 (en) 2007-03-30 2008-10-09 Sifi S.P.A. Pharmaceutical formulations based on apolar and polar lipids for ophthalmic use
WO2010039535A1 (en) * 2008-09-23 2010-04-08 Meta Cosmetics, Llc Compositions and methods to treat epithelial-related conditions
US20100104654A1 (en) 2008-10-27 2010-04-29 Allergan, Inc. Prostaglandin and prostamide drug delivery systems and intraocular therapeutic uses thereof
US8722739B2 (en) 2008-10-29 2014-05-13 Novaer Holdings, Inc. Amino acid salts of prostaglandins
CN101427993A (zh) 2008-11-20 2009-05-13 沈阳万爱普利德医药科技有限公司 前列腺素微乳凝胶制剂及其制备方法
EP2228058A1 (en) * 2009-03-04 2010-09-15 Novagali Pharma S.A. Anionic oil-in-water emulsion containing prostaglandins and uses thereof
US20110124736A1 (en) 2009-11-09 2011-05-26 Allergan, Inc. Compositions and methods for stimulating hair growth
EP2389939A1 (en) * 2010-05-28 2011-11-30 Novagali Pharma S.A. Use of prostaglandins F2alpha and analogues for the healing of corneal and conjunctival lesions
JP6042343B2 (ja) * 2010-11-18 2016-12-14 スティーヴン ヨーリン 毛髪成長のための組成物及び方法
WO2013172838A1 (en) 2012-05-17 2013-11-21 Steven Yoelin Compositions and methods for hair growth
JP5778781B2 (ja) 2011-01-19 2015-09-16 トポカイン セラピューティックス， インコーポレイテッド 代謝症候群を治療する方法および組成物
CN103459368B (zh) 2011-02-14 2016-06-08 阿勒根公司 比马前列素组合物的酯衍生物和方法
US20120251613A1 (en) * 2011-03-29 2012-10-04 Agila Specialities Pvt. Ltd. Method for treating vitiligo with a prostaglandin analogue
JP2012250950A (ja) * 2011-06-06 2012-12-20 Santen Pharmaceut Co Ltd アデノシン誘導体とプロスタグランジン類の組合せ剤
MX2014000781A (es) * 2011-07-20 2014-04-30 Allergan Inc Dosis combinada fija de bimatoprost y brimonidina.
US20130035338A1 (en) * 2011-08-05 2013-02-07 Gordon Tang Eyelid treatment
US8426471B1 (en) 2011-12-19 2013-04-23 Topokine Therapeutics, Inc. Methods and compositions for reducing body fat and adipocytes
KR20140043562A (ko) 2012-09-24 2014-04-10 한국콜마주식회사 무복계면 라타노프로스트 및 그 제조방법
US8778981B2 (en) 2012-11-21 2014-07-15 Topokine Therapeutics, Inc. Methods and compositions for locally increasing body fat
NO2753788T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) * 2013-05-10 2018-06-16
US9820993B2 (en) 2013-05-15 2017-11-21 Topokine Therapeutics, Inc. Methods and compositions for topical delivery of prostaglandins to subcutaneous fat
WO2015200425A1 (en) 2014-06-27 2015-12-30 Topokine Therapeutics, Inc. Topical dosage regimen

Also Published As

Publication number Publication date
AU2014262495B2 (en) 2019-07-18
AU2014262495B9 (en) 2019-07-25
CR20150652A (es) 2016-06-01
MX2020002881A (es) 2020-07-22
CN105209015A (zh) 2015-12-30
HK1213200A1 (zh) 2016-06-30
NO2753788T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2018-06-16
WO2014183045A2 (en) 2014-11-13
PT3124015T (pt) 2018-05-10
US20150231251A1 (en) 2015-08-20
RU2635864C2 (ru) 2017-11-16
US20200282059A1 (en) 2020-09-10
EP2863886A2 (en) 2015-04-29
PL2863886T3 (pl) 2017-03-31
PH12015502503B1 (en) 2016-02-22
ES2604160T3 (es) 2017-03-03
US9040584B2 (en) 2015-05-26
PL3124015T3 (pl) 2018-09-28
KR20200037458A (ko) 2020-04-08
EP3124015A1 (en) 2017-02-01
PT2863886T (pt) 2016-12-02
EP3395328A1 (en) 2018-10-31
NZ730201A (en) 2021-01-29
AU2014262495A1 (en) 2015-10-22
US10556012B2 (en) 2020-02-11
US20220152206A1 (en) 2022-05-19
HUE030977T2 (en) 2017-06-28
EP2863886B1 (en) 2016-08-24
US20150105462A1 (en) 2015-04-16
US9849179B2 (en) 2017-12-26
SG10201604659QA (en) 2016-07-28
KR101651450B1 (ko) 2016-08-26
SG11201600068WA (en) 2016-02-26
CY1118654T1 (el) 2017-07-12
DK2863886T3 (en) 2016-12-12
ES2670323T3 (es) 2018-05-30
HUE037405T2 (hu) 2018-08-28
JP2016135810A (ja) 2016-07-28
BR112015028290A2 (pt) 2017-07-25
CA2907721A1 (en) 2014-11-13
KR20160102326A (ko) 2016-08-29
DK3124015T3 (en) 2018-06-06
ZA201507702B (en) 2016-11-30
JP2016518416A (ja) 2016-06-23
NZ712784A (en) 2017-03-31
KR102098987B1 (ko) 2020-04-08
CL2015003270A1 (es) 2016-07-08
IL240807A (en) 2017-04-30
AU2019250230A1 (en) 2019-11-07
MY183193A (en) 2021-02-18
MX347969B (es) 2017-05-18
MX2015015535A (es) 2016-02-09
CN109966240A (zh) 2019-07-05
WO2014183045A3 (en) 2015-01-29
RU2015141767A (ru) 2017-04-06
US20180200372A1 (en) 2018-07-19
CN105209015B (zh) 2018-11-20
SI2863886T1 (sl) 2017-01-31
CA2907721C (en) 2016-02-23
AU2021221900A1 (en) 2021-09-23
IL251448A0 (en) 2017-05-29
KR20150133865A (ko) 2015-11-30
EP3124015B1 (en) 2018-03-28
JP5930568B1 (ja) 2016-06-08
IL251448B (en) 2021-01-31
PH12015502503A1 (en) 2016-02-22

Similar Documents

Publication Publication Date Title
KR102098987B1 (ko) 프로스타글란딘을 피하 지방으로 국소 전달하기 위한 조성물 및 방법
JP5700741B2 (ja) 体脂肪および脂肪細胞を減少させるための方法および組成物
US20230330105A1 (en) Methods and compositions for topical delivery of prostaglandins to subcutaneous fat
US8883834B2 (en) Methods and compositions for locally increasing body fat
HK1263095A1 (en) Compositions and methods for topical delivery of prostaglandins to subcutaneous fat
HK1233926A1 (en) Compositions and methods for topical delivery of prostaglandins to subcutaneous fat
HK1213200B (zh) 向皮下脂肪局部递送前列腺素的组合物和方法

Legal Events

Date Code Title Description
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20210402

Application number text: 1020207009488

Filing date: 20200401

PG1501 Laying open of application
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20210427

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20210607

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20211210

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20210607

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I